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Subcommittee of the American Academy of Neurology and the American Epilepsy
Society
ABSTRACT
Objective: To determine the incidence rates of sudden unexpected death in epilepsy (SUDEP) in
different epilepsy populations and address the question of whether risk factors for SUDEP have
been identified.
Methods: Systematic review of evidence; modified Grading Recommendations Assessment,
Development, and Evaluation process for developing conclusions; recommendations developed
by consensus.
Results: Findings for incidence rates based on 12 Class I studies include the following: SUDEP
risk in children with epilepsy (aged 0–17 years) is 0.22/1,000 patient-years (95% confidence
interval [CI] 0.16–0.31) (moderate confidence in evidence). SUDEP risk increases in adults to 1.2/
1,000 patient-years (95% CI 0.64–2.32) (low confidence in evidence). The major risk factor for
SUDEP is the occurrence of generalized tonic-clonic seizures (GTCS); the SUDEP risk increases
in association with increasing frequency of GTCS occurrence (high confidence in evidence).
Recommendations: Level B: Clinicians caring for young children with epilepsy should inform parents/
guardians that in 1 year, SUDEP typically affects 1 in 4,500 children; therefore, 4,499 of 4,500
children will not be affected. Clinicians should inform adult patients with epilepsy that SUDEP typ-
ically affects 1 in 1,000 adults with epilepsy per year; therefore, annually 999 of 1,000 adults will
not be affected. For persons with epilepsy who continue to experience GTCS, clinicians should con-
tinue to actively manage epilepsy therapies to reduce seizures and SUDEP risk while incorporating
patient preferences and weighing the risks and benefits of any new approach. Clinicians should
inform personswith epilepsy that seizure freedom, particularly freedom fromGTCS, is strongly asso-
ciated with decreased SUDEP risk. Neurology® 2017;88:1674–1680
GLOSSARY
AAN 5 American Academy of Neurology; AED 5 antiepileptic drug; CI 5 confidence interval; GTCS 5 generalized tonic-
clonic seizures; SUDEP 5 sudden unexpected death in epilepsy.
This document summarizes information provided in
the complete guideline, available at Neurology.org.
Appendix e-6, cited in the full guideline (data supple-
ment), is available at Neurology.org.
Sudden unexpected death in epilepsy (SUDEP) is
a poorly understood and catastrophic risk of epilepsy.
The sensitive nature of discussions of this infrequent
but important risk with patients and families has
prompted the need for evidence-based information
about SUDEP. The goal of this practice guideline is
to examine evidence for the SUDEP incidence rate
in epilepsy populations and for prognostic factors
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for SUDEP occurrence. This in turn will inform an
honest and balanced discussion when clinicians coun-
sel people about SUDEP, and provide insight into
areas where more clinical research is needed.
Two questions were asked:
1. What is the incidence rate of SUDEP in different
epilepsy populations?
2. Are there specific risk factors for SUDEP?
DESCRIPTION OF THE ANALYTIC PROCESS This
practice guideline broadly follows the process delin-
eated in the 2004 American Academy of Neurology
(AAN) guideline development process manual,1
with the exception of the processes for formulating
conclusions and recommendations, which follow the
processes explained in the 2011 AAN guideline
development process manual.2
In 2010, the AAN Guideline Development, Dis-
semination, and Implementation Subcommittee and
the Guidelines Committee of the American Epilepsy
Society convened a panel of experts to develop this
practice guideline. The guideline panel engaged
an independent medical librarian to search the
MEDLINE and Embase databases from earliest avail-
able article to November 2010. The panel then per-
formed an identical search in April 2015 to include
articles published since November 2010. The key-
words for both searches were SUDEP or (sudden
and [unexplained or unexpected] and death) combined
with the traditional medical subheadings (MeSH) for
epilepsy (epilepsy/abnormalities or epilepsy/classifica-
tion or epilepsy/complications or epilepsy/drug effects
or epilepsy/drug therapy or epilepsy/epidemiology or
epilepsy/ethnology or epilepsy/etiology or epilepsy/
genetics or epilepsy/mortality or epilepsy/physiopa-
thology or epilepsy/prevention and control or epi-
lepsy/therapy) with limits of humans, plus all child:
0–18 years or all adult: 191 years. Literature types
were limited to clinical trial; randomized controlled
trial; comparative study; controlled clinical trial; eval-
uation studies; journal article; multicenter study;
research support; NIH, extramural, research support;
NIH, intramural, research support; non–US gov’t,
research support; US gov’t, non PHS, research sup-
port; or US gov’t, PHS, validation studies. Finally,
the guideline panel specifically searched causes impli-
cated in SUDEP (i.e., cardiac arrhythmias and preictal
autonomic dysfunction), where the hypotheses were
tested.
This search yielded 1,068 abstracts, all of which
were reviewed for relevance by at least 2 panel mem-
bers working independently of each other; 744 ab-
stracts were not relevant to provide answers to the
questions. Of the remaining 324 abstracts, 2 panel
members then obtained the full articles and reviewed
them independently for inclusion. Reviewed articles
were entered into a database application through an
online questionnaire. Seventy articles had data for
inclusion, and 254 were excluded because they failed
to address the questions, employ an adequate SUDEP
definition, or use an appropriate epilepsy comparison
group in the prognostic studies. The available litera-
ture consisted of multiple Class I articles for inci-
dence, and therefore articles rated Class II or lower
were excluded because the Class II publications did
not address populations not otherwise encompassed
by the Class I articles. Several Class I and multiple
Class II articles were available for prognostic
questions.
Included articles were required to state that the
SUDEP definition provided by Nashef,3 Annegers,4
and Leestma et al.5 was used or to describe criteria in
accordance with these definitions. These definitions
share the following criteria, and the guideline panel
included any article that incorporated these criteria in
its SUDEP definition: (1) the patient had epilepsy by
reasonable criteria without reference to the criteria
used for epilepsy; (2) deaths by drowning, trauma,
or status epilepticus were excluded; (3) death could
have occurred after a witnessed seizure; (4) other
competing causes of death were excluded.
The guideline panel used 2 of the AAN’s evidence-
based schemes to rate articles: the screening criteria
for the incidence question and the prognostic criteria
for the risk factor question.
Question 1: What is the incidence of SUDEP in different
epilepsy populations? Twelve Class I studies provided
incidence rate data.6–17 Imprecision in study findings
resulted in moderate confidence in the evidence for
SUDEP rates in childhood and low confidence in the
evidence for SUDEP rates in adulthood and overall
(table 1). Because of imprecision in the incidence
study results with a lack of overlap of 95% confidence
interval (CIs) between several comparable study pop-
ulations, the guideline panel performed a random-
effects meta-analysis to provide summary measures
of the absolute or relative risk of SUDEP. In
addition, to explore reasons for heterogeneity in the
absolute risk of SUDEP reported, the panel
conducted a meta-analysis of subgroups of studies
Table 1 Conclusions for sudden unexpected
death in epilepsy (SUDEP) incidence
Population
SUDEP/1,000 patient-years
(confidence interval) Confidence
Overall 0.58 (0.31–1.08) Low
Childhood 0.22 (0.16–0.31) Moderate
Adulthood 1.2 (0.64–2.32) Low
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including different groups of patients with epilepsy
(e.g., children vs adults). These meta-analyses have
significant unexplained heterogeneity, which
may suggest the presence of other unknown or
unexplored risk factors.
Rationale for recommendations 1 and 2.Our systematic
review found that the SUDEP risk in children with
epilepsy is 0.22/1,000 patient-years (95% CI 0.16–
0.31). The SUDEP risk increases in adults to 1.2/
1,000 patient-years (95% CI 0.64–2.32). There is
considerable uncertainty regarding the estimates of
the adult risk.
People with epilepsy and their families prefer to be
informed of the individual’s risk for a catastrophic
event such as SUDEP, even when the probability of
the event is low.18 This preference is subject to cul-
tural influences. After being informed of an adverse
event, people commonly overestimate the risk of that
adverse event happening to them.19 Such overestima-
tion unduly increases anxiety related to an adverse
event. Overestimation can be lessened by presenting
the risk as the probability of both having and not
having the event,20 and by using numbers in addition
to words19 and frequencies rather than percentages to
convey the risk.21
Incidence recommendation 1: SUDEP incidence in
children. Clinicians caring for children with epilepsy
should inform the children’s parents or guardians that
(Level B for the following):
1. There is a rare risk of SUDEP.
2. In 1 year, SUDEP typically affects 1 in 4,500
children with epilepsy; in other words, annually,
4,499 of 4,500 children will not be affected by
SUDEP.
Incidence recommendation 2: SUDEP incidence in adults.
Clinicians should inform adult persons with epilepsy
that (Level B for the following):
1. There is a small risk of SUDEP.
2. In 1 year, SUDEP typically affects 1 in 1,000
adults with epilepsy; in other words, annually,
999 of 1,000 adults will not be affected by
SUDEP.
Question 2: Are there any risk factors for SUDEP? Six
Class I14,22–26 and 16 Class II articles6,7,17,23,27–38 pro-
vided evidence for this question. Table 2 summarizes
the results.
Rationale for recommendation 3. Our systematic
review found that a major risk factor for SUDEP is
the presence and frequency of generalized tonic-
clonic seizures (GTCS). For example, people with 3
or more GTCS per year have a 15-fold increased risk
of SUDEP. This relative risk increase translates to an
absolute risk of up to 18 deaths per 1,000 patient-
years for people with frequent GTCS.29
The large SUDEP risk increase from GTCS, cou-
pled with epilepsy monitoring unit evidence39 dem-
onstrating that a GTCS was always the precipitating
event of SUDEP, strongly suggests that GTCS are
not just associated with SUDEP but, rather, are in
the causal path to SUDEP. From this, it seems rea-
sonable to infer that improved control of an individ-
ual’s GTCS will result in a reduced risk of SUDEP.
Thus, a reduction in SUDEP risk is an additional
benefit to the many benefits resulting from improved
seizure control.
As with all benefits associated with improved sei-
zure control, the potential benefit of SUDEP risk
reduction needs to be balanced with the risks and
burdens associated with antiseizure therapies.
Recommendation 3. For persons with epilepsy who
continue to experience GTCS, clinicians should con-
tinue to actively manage epilepsy therapies to reduce
seizure occurrences and the risk of SUDEP while
incorporating patient preferences and weighing the
risks and benefits of any new approach (Level B).
Rationale for recommendation 4. GTCS are clear risk
factors for SUDEP, and nocturnal seizures may also
increase risk. These findings, in conjunction with
the observation that postictal respiratory depression
is a major mechanism in SUDEP,39 suggest that un-
witnessed nocturnal seizures and postictal respiratory
depression can cause SUDEP.
Moreover, the presence in the bedroom of another
individual at least 10 years of age and of normal intel-
ligence is associated with a decreased SUDEP risk.
These results imply that a bedroom observer could
detect seizures, check on the patient, and provide suf-
ficient stimulation to prevent respiratory arrest. This
association does not indicate that these interventions
directly mitigate the mechanism that causes SUDEP.
If it were in accordance with patient and family
circumstances and values, nocturnal supervision
Table 2 Conclusions for sudden unexpected death in epilepsy (SUDEP) risk
factors
Factor OR (CI) Confidence level
Presence of GTCS vs lack of
GTCS
10 (17–14) Moderate
Frequency of GTCS OR 5.07 (2.94–8.76) for 1–2 GTCS
per year and OR 15.46 (9.92–
24.10) for .3 GTCS per year
High
Not being seizure-free for 1–5 y 4.7 (1.4–16) Moderate
Not adding an AED when
patients are medically
refractory
6 (2–20) Moderate
Nocturnal supervision (risk
reduction)
0.4 (0.2–0.8) Moderate
Use of nocturnal listening
device (risk reduction)
0.1 (0–0.3) Moderate
Abbreviations: AED 5 antiepileptic drug; CI 5 confidence interval; GTCS 5 generalized
tonic-clonic seizure; OR 5 odds ratio.
1676 Neurology 88 April 25, 2017
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
could reduce SUDEP risk; however, providing night-
time observation might be overly burdensome and
intrusive.
Recommendation 4. For persons with frequent
GTCS and nocturnal seizures, clinicians may advise
selected patients and families, if permitted by their
individualized epilepsy and psychosocial circumstan-
ces, to use nocturnal supervision or other nocturnal
precautions, such as the use of a remote listening
device, to reduce SUDEP risk (Level C).
Rationale for recommendation 5.One of the most con-
sistent findings of this review is that many factors that
are indicators of uncontrolled epilepsy, including hav-
ing GTCS, having frequent GTCS, and the absence
of seizure freedom, are strongly associated with
SUDEP.
Usually, people with epilepsy and their families
prefer to be informed of factors that are associated
with an increased risk of a catastrophic event such
as SUDEP. Patients are especially interested in factors
that might reduce their risk even when a causal link
between the factor and a reduction in risk has not
been established. Knowledge of these risk factors
might suggest behaviors that could modify the risk
factors (e.g., improved therapy adherence40), increase
the person’s sense of control, and reduce the anxiety
that comes from awareness of the risk. Less severe
seizure types, such as focal seizures or myoclonic seiz-
ures, are not proven to be associated with increased
SUDEP risk, but individuals who have them often
remain at risk for GTCS in the setting of therapy
nonadherence. Therefore, therapy adherence to
maintain freedom from GTCS is important even
when an individual is not experiencing this severe
seizure type.
Recommendation 5. Clinicians should inform pa-
tients with epilepsy that seizure freedom, particularly
freedom from GTCS (which is more likely to occur
with medication adherence), is strongly associated
with a decreased risk of SUDEP (Level B).
Additional conclusions (no recommendations made). The
evidence is low that the following factors are associ-
ated with altering SUDEP risk:
1. Nocturnal seizures (associated with increased
risk)
2. Any specific antiepileptic drug (AED) (none
associated specifically with increased risk)
3. Lamotrigine use in women (associated with
increased risk)
4. Never having been treated with an AED (associ-
ated with increased risk)
5. Number of AEDs used overall (associated with
increased risk)
6. Heart rate variability (not associated with
increased risk)
7. Extratemporal epilepsy (associated with
increased risk)
8. Intellectual disability (associated with increased
risk)
9. Male sex (associated with increased risk)
10. Anxiolytic drug use (associated with increased
risk)
The evidence is very low or conflicting that the fol-
lowing factors are associated with altering SUDEP
risk:
1. Overall seizure frequency when evaluated by
using all seizure types
2. Medically refractory epilepsy vs not having well-
controlled seizures defined as no seizures in the
last year
3. Monotherapy vs polytherapy
4. Carbamazepine, phenytoin, or sodium valproate
levels that are above, below, or within the refer-
ence range
5. Psychotropic drug use
6. Mental health disorders, lung disorders, or alco-
hol use
7. Lamotrigine use in people with highly refractory
epilepsy
8. Frequent changes in AEDs
9. Therapeutic drug monitoring
10. Undergoing a resective epilepsy surgical proce-
dure (although current research does not rule
out the possibility of a beneficial effect or, fur-
ther, the potential effect of epilepsy surgery on
reducing GTCS frequency and epilepsy severity
on reducing SUDEP risk)
11. Engel outcome of epilepsy surgery (although cur-
rent research does not rule out the possibility of
a beneficial effect and, further, the potential
effect of epilepsy surgery on reducing GTCS fre-
quency and epilepsy severity on reducing
SUDEP risk)
12. Vagus nerve stimulator use for more than 2 years
(however, current research does not rule out the
possibility of a beneficial effect and, further, the
potential effect of epilepsy surgery on reducing
GTCS frequency and epilepsy severity on reduc-
ing the risk of SUDEP)
13. Epilepsy etiology, whether idiopathic or localiza-
tion-related
14. Structural lesion on MRI
15. Duration of epilepsy
16. Age at epilepsy onset
17. Postictal EEG suppression
SUGGESTIONS FOR FUTURE RESEARCH
1. Systematic methods should be developed to iden-
tify and report the incidence of SUDEP in
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different epilepsy populations in order to obtain
a better understanding of the incidence and causes
of this devastating condition.
2. Educational efforts are needed to improve the
forensic knowledge of SUDEP among professio-
nals such as medical examiners, coroners, and
pathologists in order to help determine, and doc-
ument on death certificates, the etiology in indi-
viduals, and in order to improve overall knowledge
of this condition.
3. Research to identify preventable risk factors
should be supported and encouraged so that
future clinical trials will be conducted to reduce
SUDEP occurrence. Of particular importance is
to better understand (1) the relationship between
the nature, severity, and duration of epilepsy and
the occurrence of SUDEP and (2) whether current
treatments affect the risk of developing SUDEP.
4. Because of (1) risks identified with frequent
GTCS, (2) the fact that one study shows more
SUDEP events occur in people in placebo arms
of trials, and (3) increased SUDEP risk, serious
consideration should be given to avoid assigning
people with frequent GTCS to placebo for long
periods.
DISCLAIMER Clinical practice guidelines, practice
advisories, systematic reviews and other guidance
published by the American Academy of Neurology
and its affiliates are assessments of current
scientific and clinical information provided as an
educational service. The information: (1) should
not be considered inclusive of all proper
treatments, methods of care, or as a statement of
the standard of care; (2) is not continually
updated and may not reflect the most recent
evidence (new evidence may emerge between the
time information is developed and when it is
published or read); (3) addresses only the
questions specifically identified; (4) does not
mandate any particular course of medical care;
and (5) is not intended to substitute for the
independent professional judgment of the treating
provider, as the information does not account for
individual variation among patients. In all cases,
the selected course of action should be considered
by the treating provider in the context of treating
the individual patient. Use of the information is
voluntary. AAN provides this information on an “as
is” basis, and makes no warranty, expressed or implied,
regarding the information. AAN specifically disclaims
any warranties of merchantability or fitness for
a particular use or purpose. AAN assumes no
responsibility for any injury or damage to persons or
property arising out of or related to any use of this
information or for any errors or omissions.
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